Glucocorticoids increase the number of insulin receptors in cultured human lymphocytes. This effect is specific for the insulin receptor as growth hormone receptor concentration decreases. The effect is time-dependent, dose-dependent over the physiologic concentration range of glucocorticoid, reversible, and appears to be mediated via specific glucocorticoid receptors. Protein synthesis and glycosylation are required as the effect is inhibited by actinomycin D, puromycin, cycloheximide, and tunicamycin. Isolated solubilized plasma membranes, as well as solubilized whole cells from glucocorticoid-treated lymphocytes, show the same increase in insulin receptors as do intact cells. The glucocorticoid-induced receptors are immunologically indistinguishable from control when precipitated by anti-receptor antibody. Glucocorticoids do not stabilize existing receptors since the degradation rate of receptors is actually increased. Regulation of the insulin receptor by insulin is independent of the steroid effect. However, there is a right-ward shift of the dose-response curve for "down regulation" by insulin in the presence of glucocorticoid. We conclude that glucocorticoids increase the number of insulin receptors in cultured human lymphocytes by increasing the synthesis of new receptors. This represents the first induction of insulin receptor synthesis by a pharmacologic agent.

Download full-text PDF

Source

Publication Analysis

Top Keywords

insulin receptors
16
receptors cultured
12
cultured human
12
human lymphocytes
12
insulin receptor
12
insulin
9
receptors
9
increase insulin
8
glucocorticoids increase
8
increase number
8

Similar Publications

Multiple myeloma (MM) remains an incurable hematological malignancy that necessitates the identification of novel therapeutic strategies. Here, we report that intracellular levels of very long chain fatty acids (VLCFAs) control the cytotoxicity of MM chemotherapeutic agents. Inhibition of VLCFA biosynthesis reduced cell death in MM cells caused by the proteasome inhibitor, bortezomib.

View Article and Find Full Text PDF

D-allulose enhances lipid oxidation in HepG2 cells via peroxisome proliferator-activated receptor α (PPARα).

Biochim Biophys Acta Mol Cell Biol Lipids

January 2025

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida Jacksonville College of Medicine, Jacksonville, FL 32209, United States of America.

Lipid accumulation in hepatocytes in non-alcoholic steatohepatitis (NASH) is attributed partly to loss of insulin-responsiveness and/or an increased pro-inflammatory state. Since the rare sugar D-allulose has insulin mimetic and anti-inflammatory properties, its effects on lipid accumulation in liver-derived cells was tested. In HepG2 cells exposed to 200 μM oleic acid for 72 h, D-allulose treatment decreased intracellular lipid accumulation with an IC = 0.

View Article and Find Full Text PDF

Obesity and its associated metabolic disorders are significant global health challenges, necessitating novel therapeutic approaches. This study explores the anti-adipogenic and anti-dyslipidemic properties of 4655-EF, a novel phytopharmaceutical derived from Polyalthia longifolia, and explores the molecular pathways involved in its pharmacological activity. This phytopharmaceutical was prepared using a bioactivity-guided supercritical fluid extraction method suitable for large-scale production.

View Article and Find Full Text PDF

The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and updates recommendations on the principles of intensive insulin regimens, including more intensive forms of multiple daily injections with new-generation faster-acting and ultra-long-acting insulins; a summary of adjunctive medications used alongside insulin treatment that includes details on pramlintide, metformin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) and sodium-glucose cotransporter inhibitors; and key considerations with regard to access to insulin and affordability to ensure that all persons with diabetes who need insulin can obtain it without financial hardship.

View Article and Find Full Text PDF

Uncovering the intricacies of IGF-1 in Alzheimer's disease: new insights from regulation to therapeutic targeting.

Inflammopharmacology

January 2025

Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, 142001, Punjab, India.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β plaques and tau tangles, leading to cognitive decline and dementia. Insulin-like Growth Factor-1 (IGF-1) is similar in structure to insulin and is crucial for cell growth, differentiation, and regulating oxidative stress, synaptic plasticity, and mitochondrial function. IGF-1 exerts its physiological effects by binding to the IGF-1 receptor (IGF-1R) and activating PI3K/Akt pathway.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!